TEPRO
Drug
Horizon Pharma plc
Total Payments
$1.2M
Transactions
242
Doctors
166
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.2M | 234 | 161 |
| 2017 | $7,858 | 8 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.2M | 12 | 94.0% |
| Honoraria | $44,400 | 17 | 3.6% |
| Food and Beverage | $18,685 | 193 | 1.5% |
| Travel and Lodging | $12,019 | 20 | 1.0% |
Payments by Type
Research
$1.2M
12 transactions
General
$75,104
230 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TEPRO 301 | Horizon Pharma plc | $1.0M | 0 |
| MULTICENTER SAFETY AND EFFICACY OPEN-LABEL EXTENSION STUDY EVALUATING TEPROTUMUMAB HZN-001 TREATMENT IN SUBJECTS WITH ACTIVE THYROID EYE DISEASE | Horizon Pharma plc | $141,028 | 0 |
Top Doctors Receiving Payments for TEPRO
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $1.2M | 12 |
| , MD | Ophthalmology | Stockton, CA | $3,868 | 4 |
| , MD | Ophthalmology | Philadelphia, PA | $3,848 | 5 |
| , MD PHD | Ophthalmology | Salt Lake City, UT | $3,796 | 5 |
| , MD | Facial Plastic Surgery | Indianapolis, IN | $3,739 | 4 |
| , MD | Ophthalmology | Denver, CO | $3,738 | 3 |
| , MD | Ophthalmology | Madison, WI | $3,738 | 3 |
| , MD, PHD | Ophthalmology | Ann Arbor, MI | $3,613 | 10 |
| , M.D | Ophthalmology | Ann Arbor, MI | $3,472 | 4 |
| , MD | Plastic and Reconstructive Surgery | Saint Louis, MO | $3,156 | 4 |
| , M.D | Ophthalmology | Minneapolis, MN | $3,138 | 3 |
| , MD | Ophthalmology | Houston, TX | $3,138 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Washington, DC | $2,300 | 4 |
| , MD, FRCP | Endocrinology, Diabetes & Metabolism | New York, NY | $2,236 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rochester, MN | $2,236 | 3 |
| , MD | Endocrinology, Diabetes & Metabolism | Sarasota, FL | $1,936 | 3 |
| , MD | Internal Medicine | Boston, MA | $1,936 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rochester, MN | $1,936 | 3 |
| , MD | Internal Medicine | Indianapolis, IN | $1,636 | 3 |
| , M.D | Ophthalmology | Houston, TX | $1,554 | 3 |
| , MD | Ophthalmology | Portland, OR | $1,441 | 1 |
| , M.D | Internal Medicine | Ann Arbor, MI | $1,103 | 1 |
| , MD | Ophthalmology | Milwaukee, WI | $800.78 | 1 |
| , MD | Ophthalmology | Portland, OR | $680.48 | 1 |
| , M.D | Ophthalmology | Panorama City, CA | $373.96 | 3 |
Ad
Manufacturing Companies
- Horizon Pharma plc $1.2M
Product Information
- Type Drug
- Total Payments $1.2M
- Total Doctors 166
- Transactions 242
About TEPRO
TEPRO is a drug associated with $1.2M in payments to 166 healthcare providers, recorded across 242 transactions in the CMS Open Payments database. The primary manufacturer is Horizon Pharma plc.
Payment data is available from 2017 to 2018. In 2018, $1.2M was paid across 234 transactions to 161 doctors.
The most common payment nature for TEPRO is "Unspecified" ($1.2M, 94.0% of total).
TEPRO is associated with 2 research studies, including "TEPRO 301" ($1.0M).